Clinical trials
13 active studies led by Genoss Co., Ltd., of 18 in all
Source: ClinicalTrials.gov, Studies with Genoss Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show Genoss Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Genoss Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: Wikidata, Company record Q20445882. Retrieved 13 Nov 2026.
13 active studies led by Genoss Co., Ltd., of 18 in all
Source: ClinicalTrials.gov, Studies with Genoss Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
18 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Studies Genoss Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Genoss Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Genoss Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Genoss Co., Ltd. is in.
Stories on the topics Genoss Co., Ltd. works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
Read
2.4 billion people live with a condition that could benefit from rehabilitation. The need rose 63% since 1990.
Read